Insmed Incorporated (NASDAQ:INSM) Stock Position Raised by Blue Trust Inc.

Blue Trust Inc. grew its position in shares of Insmed Incorporated (NASDAQ:INSM) by 25.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,462 shares of the biopharmaceutical company’s stock after acquiring an additional 503 shares during the period. Blue Trust Inc.’s holdings in Insmed were worth $180,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in INSM. CIBC Asset Management Inc lifted its stake in Insmed by 3.5% in the third quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 149 shares during the last quarter. Commerce Bank lifted its stake in shares of Insmed by 2.4% in the 3rd quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 163 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Insmed by 5.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 183 shares in the last quarter. GAMMA Investing LLC increased its position in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares during the last quarter. Finally, Atomi Financial Group Inc. raised its holdings in Insmed by 1.4% during the third quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company’s stock valued at $1,697,000 after buying an additional 314 shares in the last quarter.

Wall Street Analyst Weigh In

INSM has been the subject of several recent analyst reports. Truist Financial reiterated a “buy” rating and set a $105.00 price target (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. upped their target price on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, November 22nd. Bank of America boosted their target price on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Insiders Place Their Bets

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the transaction, the insider now owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. This represents a 48.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Sara Bonstein sold 1,066 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.72, for a total transaction of $67,925.52. Following the transaction, the chief financial officer now owns 118,863 shares of the company’s stock, valued at approximately $7,573,950.36. This represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 195,880 shares of company stock valued at $14,452,494 in the last 90 days. 4.60% of the stock is currently owned by insiders.

Insmed Trading Up 4.0 %

Shares of INSM opened at $81.01 on Wednesday. The stock has a fifty day moving average price of $72.58 and a two-hundred day moving average price of $72.99. The company has a market cap of $14.49 billion, a price-to-earnings ratio of -14.60 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $81.25.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.